双鹭药业：第三季度归母净利润同比增长143.28%

Core Viewpoint - Shuanglu Pharmaceutical reported a revenue of 154 million yuan for Q3 2025, marking a year-on-year growth of 3.63% and a net profit attributable to shareholders of 20.05 million yuan, reflecting a significant increase of 143.28% [1] Financial Performance - The company achieved a revenue of 154 million yuan in Q3 2025, which is a 3.63% increase compared to the same period last year [1] - The net profit attributable to shareholders reached 20.05 million yuan, showing a remarkable growth of 143.28% year-on-year [1] - Basic earnings per share were reported at 0.0195 yuan [1]